板块跌幅居前的股票包括：ST凯利（-6.72%）、浩欧博（-4.36%）、泰林生物（-2.04%）、山外山 （-1.71%）、博拓生物（-1.59%）、奕瑞科技（-1.35%）、DR三友医（-1.31%）、济高发展 （-1.24%）、安旭生物（-1.21%）、爱迪特（-0.89%）、麦澜德（-0.87%）、锦好医疗（-0.86%）、康 众医疗（-0.51%）、瑞迈特（-0.44%）、九安医疗（-0.44%）、理邦仪器（-0.39%）、西山科技 （-0.38%）、明德生物（-0.38%）、鹿得医疗（-0.36%）、赛诺医疗（-0.35%） 来源：金融界 7月17日，截至收盘，医疗器械行业上涨0.78%，板块资金流出17857.82万。上涨个股家数89个，下跌个 股家数31个。 序代码股票名称现价涨跌幅主力资金净额主力资金净占比1688581安杰思71.047.36-1282.82 万-7.902301093华兰股份26.45.22-589.68万-3.173688016心脉医疗101.995.11621.42万3.314688029南微医 学76.254.451979.15万7.585688236春立医疗20. ...

创业板指今日上涨1.75%，报收2269.33点，创业板全日成交额4431.23亿元，比上个交易日增加141.04亿 元。今日可交易创业板股中，1048只股收盘上涨，涨幅超过10%的有14只，其中，ST立方、满坤科技、 南京聚隆等5股涨停，涨幅在5%至10%之间的有45只，收盘下跌的有291只。 证券时报·数据宝统计显示，换手率方面，创业板今日平均换手率为4.05%，换手率区间分布显示，换手 率超过20%的有39只，换手率10%~20%之间的有149只，换手率5%~10%的有321只，换手率1%~5%的有 814只，换手率不足1%的有60只。 换手率最高的是欣灵电气，该股今日收盘上涨0.31%，全天换手率52.50%，成交额5.64亿元；其次是北 方长龙，该股今日收盘上涨5.88%，全天换手率48.34%，成交额9.66亿元；换手率居前的还有满坤科 技、铜冠铜箔、德固特等，换手率分别为45.59%、40.44%、39.50%。 从市场表现看，高换手率股中，今日上涨的有32只，ST立方、满坤科技、南京聚隆等收盘涨停，跌幅 居前的有*ST紫天、长荣股份、德固特等，分别下跌7.85%、5.49%、4.24%。 分行 ...

Suspension - Helen Piano's actual controller is planning a change in control, leading to a stock suspension [1] Private Placement - Weili Transmission plans to raise no more than 600 million yuan for the wind power gearbox smart factory (Phase I) and to supplement working capital [2] - Shenghong Technology's application for issuing shares to specific objects has been approved by the Shenzhen Stock Exchange [2] Share Buyback and Increase - Hongta Securities intends to repurchase shares worth 100 million to 200 million yuan to reduce the company's registered capital [3] - Diao Home's actual controller, along with certain directors and senior management, plans to increase their holdings by 37.5 million yuan [4] External Investment - Stik plans to invest 509 million yuan in the construction of a high-end functional film material expansion project [5] - China Resources Double Crane intends to invest 40 million yuan to establish the second phase of the China Resources Pharmaceutical Industry Investment Fund [6] - Star Ring Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [7] - Oriental Yuhong plans to acquire 100% equity of a Chilean building materials retailer for 123 million USD [8] - Changhua Group has received a designated order from a domestic new energy vehicle client, with an expected total sales amount of approximately 235 million yuan [9] - Jinlihua Electric is investing 186 million yuan to construct a production line for 3 million high-voltage glass insulators annually [10] Performance Changes - Hangzhou Bank reported a net profit of 11.662 billion yuan in the first half of the year, a year-on-year increase of 16.67% [11] - Zhongwei Company expects a net profit of 680 million to 730 million yuan in the first half, a year-on-year increase of 31.61% to 41.28% [11] - Tuojing Technology anticipates a net profit of 238 million to 247 million yuan in the second quarter, a year-on-year increase of 101% to 108% [11] - Microchip Biotech expects a net profit of 30.06 million yuan in the first half of 2025, turning from loss to profit [11]

Revenue Distribution - The automotive and engineering machinery sectors account for approximately 80% of the company's total revenue, with the automotive sector showing continuous growth and surpassing the engineering machinery sector in revenue contribution [2] - The top five customers contributed 18.49% to the company's revenue in 2024, indicating a diversified customer base without reliance on a single client [2] Capacity Utilization - The company's current capacity utilization is at a normal level, with sufficient flexibility to meet the growing demands in the automotive and robotics sectors [2] Competitive Landscape - The company positions itself in the mid-to-high-end market, facing competition from major players such as Saint-Gobain, GGB, and DaTong, while maintaining a comprehensive product system and superior product quality [3] Risk Management - The company does not engage in hedging strategies for raw material price fluctuations but has implemented a pricing mechanism that links product sales prices to raw material costs to mitigate price volatility [3] - Plans to enhance core technological innovation capabilities through increased R&D investment and optimization of product structure are in place to improve profitability [3] Product Advantages in Robotics - The company specializes in self-lubricating bearings, with products designed to meet the demands of impact resistance, maintenance-free operation, lightweight, low cost, low noise, and long lifespan, primarily used in robot joints, wrists, and ankles [3]

Core Viewpoint - The article highlights the increasing trend of cash dividends among listed companies in China, driven by regulatory encouragement and a focus on shareholder returns, with a record total cash dividend of over 2.3 trillion yuan expected in 2024 [1][2]. Group 1: Regulatory Environment - The China Securities Regulatory Commission revised guidelines at the end of 2023 to encourage companies to increase the frequency and level of cash dividends [1]. - The "National Nine Articles" introduced in April 2024 emphasizes the stability, continuity, and predictability of dividends, promoting multiple distributions within a year [1]. Group 2: Company Performance - A total of 13 stocks have maintained a dividend payout ratio exceeding 70% for three consecutive years, with cumulative dividends exceeding 300% of net profits [1]. - Yutong Bus has the highest cumulative dividend payout ratio at 396.98%, distributing over 8.8 billion yuan from nearly 6.7 billion yuan in net profits over three years [1]. Group 3: Recognition and Market Performance - Jinhui Co., Ltd. received the "China Listed Company Investor Relations Shareholder Return Tianma Award" for its commitment to shareholder returns, having distributed over 1.434 billion yuan in cash dividends since its A-share market debut in 2022 [2]. - Jinhui's stock has seen a year-to-date increase of nearly 15%, leading the market in performance [2]. Group 4: Future Dividend Plans - Aoputech has announced a dividend plan to distribute at least 50% of its distributable profits in cash annually over the next three years [3]. - Jinhui plans to distribute at least 30% of its distributable profits in cash annually from 2025 to 2027 [3]. Group 5: High Dividend Stocks Performance - The article lists several high-dividend stocks with significant annual returns, including: - Jinhui Co., Ltd. with a one-year cumulative return of 333.46% and a dividend rate of 79.97% for 2024 [4]. - Aoputech with a one-year cumulative return of 327.33% and a dividend rate of 108.75% for 2024 [4]. - Yutong Bus with a cumulative return of 396.98% and a dividend rate of 80.68% for 2024 [4].

对于为何提前换届和经营业绩等问题，记者致电宝莱特并发去采访邮件，接线工作人员表示，暂无更多 回应。 距本届董事会任期届满尚有半年时间 宝莱特成立于1993年，总部位于广东省珠海市，控股股东和实际控制人为燕金元、王石夫妇，公司主营 业务为医疗器械产品研发、生产、销售、服务，主要涵盖生命信息与支持和肾病医疗两大业务板块。其 中，生命信息与支持板块主要产品为监护仪设备、心电图机、输注液泵、脉搏血氧仪、监护系统、可穿 戴医疗产品等，目前监护设备已覆盖数千家医疗机构。 7月16日晚间，血透龙头宝莱特（300246.SZ，股价9.11元，市值24.1亿元）发布董事会提前换届公告 称，第八届董事会任期即将于2025年12月届满，结合公司实际情况，公司拟开展董事会提前换届选举工 作。 肾病医疗板块，主要产品为血液透析设备（机）、血液透析器、透析液过滤器、血液透析粉/透析液、 透析管路、穿刺针、消毒液、透析用制水设备等，广泛应用于急慢性肾功能衰竭领域的治疗。 根据公告，宝莱特第八届董事会非独立董事陈坚、廖伟、唐文普将不再担任公司非独立董事职务，陈坚 拟提名为第九届董事会独立董事。此次提前换届后，宝莱特第九届董事会拟由9名董事组 ...

Core Insights - Medtronic is transforming its strategy in China from being an "innovative technology exporter" to a "local ecosystem builder" by focusing on five interconnected chains: innovation integration, local manufacturing, value co-creation, intelligent services, and collaborative supply chain [1][3] Local Manufacturing - Medtronic has invested in local production capabilities, exemplified by the Mazor XC spinal surgery robot, which is a localized version of its global Mazor X series, showcasing China's ability to produce high-end medical devices [3][4] - The "Genesis Electric Stapler," developed entirely in China, was brought from research to mass production within a year and is now used in over 500 hospitals domestically and has been exported globally [4] Innovation Integration - The Lantern left bundle branch pacing catheter, developed through collaboration with Chinese clinicians, represents a significant innovation that will serve global markets, highlighting China's role in driving global medical advancements [5] - Medtronic's first localized product in neurointervention, the "Mei An Xin" coil, has been designed to meet the needs of Chinese patients and is already implanted in 28 provinces [5] Collaborative Ecosystem - Medtronic's "value co-creation chain" and "collaborative supply chain" strategies are evident in its partnerships, such as the RDN technology for hypertension treatment, which is set to be the first device approved in the U.S., EU, and China simultaneously [6] - The company has developed nearly 7,000 supply chain partners in China, with projected procurement of approximately 5 billion RMB in the fiscal year 2025, emphasizing local supplier integration [6][7] Intelligent Services - Medtronic is establishing a digital healthcare innovation base in Beijing, set to open by the end of 2025, focusing on remote management and intelligent follow-up solutions to enhance the healthcare ecosystem in China [8] - The company's long-term commitment to the Chinese market is reflected in its strategy to foster cooperation and shared progress in medical innovation [9]

| 惠升惠泽混合A | | --- | | 今年以来各阶段业绩及同类排名 | 财报显示，惠升基金旗下惠升惠泽混合A进入建设机械前十大股东，且为今年一季度新进。今年以来收益率4.65%，同类排名1106(总2296)。 | 阶段涨幅 | 年度涨幅 季度涨幅 | | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | 0.84% | 3.21% | 7.92% | 5.60% | 4.65% | | 同类平均( | 1.17% | 3.66% | 8.04% | 8.39% | 7.17% | | 沪深300 | 0.61% | 4.24% | 6.95% | 5.83% | 2.53% | | 同类排名 3 | 973 2335 | 1115 2331 | 988 2318 | 1212 2305 | 1106 2296 | | 四分位排名 2 | | | | 图片来源:天天基金网 2025/7/17 | | | | =1 4.7 | | | | | 惠升惠泽混合A基金经理分别为孙庆、钱睿南 ...

证券代码：603063 证券简称：禾望电气 公告编号：2025-068 深圳市禾望电气股份有限公司 截至本公告披露日，深圳市禾望电气股份有限公司（以下简称"公司"）副 总经理王琰先生持有公司 3,250,587 股，占公司总股本的 0.7145%；副总经理、 首席技术官周党生先生持有公司 4,460,443 股，占公司总股本的 0.9804%；副总 经理、首席运营官肖安波先生持有公司 3,784,000 股，占公司总股本的 0.8317%； 副总经理、首席财务官陈文锋先生持有公司 220,500 股，占公司总股本的 0.0485%。 ? 减持计划的主要内容 自本公告披露之日起 15 个交易日后的 3 个月内（窗口期不减持），公司副总 经理王琰先生拟以集中竞价交易方式减持不超过 812,500 股，占公司总股本的 超过 1,100,000 股，占公司总股本的 0.2418%；公司副总经理、首席运营官肖安 波先生拟以集中竞价交易方式减持不超过 946,000 股，占公司总股本的 0.2079%； 公司副总经理、首席财务官陈文锋先生拟以集中竞价交易方式减持不超过 55,000 股，占公司总股本的 0.0121%，减 ...

自首届中国国际供应链促进博览会（以下简称"链博会"）举办以来，GE医疗连续第三年携手一众核心 国产供应商参展。今年以"国产创新，韧链共赢"为主题，GE医疗集中展出了覆盖CT、磁共振、核医 学、先进可视化诊疗领域的十余款最新国产高端医械智造成果，并联合核心供应商展示了CT轴承、探 测器、磁共振超导线以及超声电路板等国产核心零部件，生动呈现了30多年来深度参与高端医械供应链 建链、强链、延链的实践成果。 展会上，GE医疗联合贝莱胜发起中国医疗设备绿色供应链创新生态圈联盟，并与中国物流与采购联合 会医疗器械供应链分会、国家高性能医疗器械创新中心和深圳市医疗器械行业协会联合主办联盟成立仪 式，洛阳轴承、西部超导、科罗诺司、中国外运等首批成员单位集体亮相。联盟成员将围绕绿色设计、 低碳制造、资源循环利用等关键环节展开深度合作，通过建立跨企业协同创新平台，整合产业链上下游 资源，共同探索医疗设备行业的绿色发展新模式，推动行业向"低能耗、低排放、高效率、高价值"的可 持续发展路径转型。 GE医疗还发布了《2024年可持续发展报告》，全面展示在负责任运营、拓展医疗可及性、推动绿色转 型等方面的最新成果与战略规划。2024年， ...